Morphic Holding, Inc. (MORF)

NASDAQ: MORF · IEX Real-Time Price · USD
37.36
-0.80 (-2.10%)
Feb 28, 2024, 2:30 PM EST - Market open
-2.10%
Market Cap 1.78B
Revenue (ttm) 521,000
Net Income (ttm) -152.10M
Shares Out 50.04M
EPS (ttm) -3.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 209,723
Open 37.46
Previous Close 38.16
Day's Range 36.93 - 38.39
52-Week Range 19.35 - 63.08
Beta 1.41
Analysts Buy
Price Target 60.29 (+61.38%)
Earnings Date Apr 23, 2024

About MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 121
Stock Exchange NASDAQ
Ticker Symbol MORF
Full Company Profile

Financial Performance

In 2023, MORF's revenue was $521,000, a decrease of -99.26% compared to the previous year's $70.81 million. Losses were -$152.10 million, 157.6% more than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is $60.29, which is an increase of 61.38% from the latest price.

Price Target
$60.29
(61.38% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

MORF ends '23 with $700 million, cash into 2H27; MORF-057 EMERALD-2 UC trial enrolling on target; to begin Ph 2 GARNET trial of 057 in Crohn's disease 1H24

6 days ago - GlobeNewsWire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdin...

4 weeks ago - Accesswire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdin...

6 weeks ago - Accesswire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF) investors concerning the Compan...

6 weeks ago - Business Wire

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdin...

6 weeks ago - Accesswire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Morphic Holding, ...

6 weeks ago - Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Morphic Holding, Inc. (“Morphic” or the “Company”) (NASDAQ: MORF) on behalf of investors concerning the Com...

7 weeks ago - Business Wire

Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference

-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology co...

7 weeks ago - GlobeNewsWire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdi...

2 months ago - Accesswire

Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)---- $MORF #MorphicHoldingInc--Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors.

3 months ago - Business Wire

Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)---- $MORF #MorphicHoldingInc--Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors.

3 months ago - Business Wire

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdi...

3 months ago - Accesswire

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023-

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)

NEW YORK , Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or the "Company") (NASDAQ: MORF). Such investors are advised t...

4 months ago - PRNewsWire

Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers, or oth...

4 months ago - Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holdin...

4 months ago - Accesswire

Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers, or oth...

4 months ago - Business Wire

MORF INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

SAN DIEGO , Oct. 13, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ...

4 months ago - PRNewsWire

Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...

5 months ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding...

5 months ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding...

5 months ago - Accesswire

MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ: MORF) focused on whether Mor...

5 months ago - Business Wire

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Hold...

5 months ago - Accesswire

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.

Other symbols: COSTCRDFMLKNPRGSTRUE
5 months ago - Market Watch

Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence

WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is tak...

5 months ago - GlobeNewsWire